| Bioactivity | Efungumab is a monoclonal antibody with antifungal activity. Efungumab binds to HSP 90, preventing a conformational change needed for fungal viability. Efungumab can be used for research on invasive candidiasis (IC)[1]. |
| In Vivo | Efungumab (2 mg/kg， i.p.， 每日一次， 持续三天) 在 CD1 小鼠念珠菌 c. albicans 传播性模型中显著降低器官上菌株的平均集落个数，并增加肝活检阴性结果[2]。 Animal Model: |
| Name | Efungumab |
| CAS | 762260-74-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Karwa R, et al. Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23. [2]. Cowen LE, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2818-23. |